西米普利单抗治疗晚期皮肤鳞状细胞癌：英国“指定患者计划”的经验 - Suppr | 超能文献

相似文献

1

Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme.西米普利单抗治疗晚期皮肤鳞状细胞癌：英国“指定患者计划”的经验

J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e590-e592. doi: 10.1111/jdv.18082. Epub 2022 Mar 24.

2

Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.晚期皮肤鳞状细胞癌患者中cemiplimab的早期停药情况。

J Geriatr Oncol. 2024 Mar;15(2):101640. doi: 10.1016/j.jgo.2023.101640. Epub 2023 Oct 3.

3

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.西妥昔单抗治疗局部晚期皮肤鳞状细胞癌：一项开放标签、2 期、单臂试验的结果。

Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14.

4

RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.瑞弗西单抗：首个获批用于治疗转移性或不可切除性皮肤鳞状细胞癌的药物。

Actas Dermosifiliogr (Engl Ed). 2020 Mar;111(2):161-163. doi: 10.1016/j.ad.2018.10.025. Epub 2019 Dec 24.

5

Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.肾移植后晚期皮肤鳞状细胞癌患者成功使用西米普利单抗治疗

JCO Oncol Pract. 2020 Mar;16(3):137-138. doi: 10.1200/JOP.19.00567. Epub 2019 Nov 26.

6

Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.新辅助西米普利单抗在局部晚期皮肤鳞状细胞癌中诱导持久完全缓解。

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1414-e1416. doi: 10.1111/jdv.19344. Epub 2023 Jul 24.

7

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.评估西妥昔单抗在治疗晚期皮肤鳞状细胞癌成人患者中的价值：成本效益分析。

Value Health. 2021 Mar;24(3):377-387. doi: 10.1016/j.jval.2020.09.014. Epub 2021 Jan 22.

8

Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.西米普利单抗治疗局部晚期皮肤鳞状细胞癌期间的放射回忆反应

Dermatol Ther. 2020 Nov;33(6):e14417. doi: 10.1111/dth.14417. Epub 2020 Oct 23.

9

Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.西米普利单抗治疗局部晚期皮肤鳞状细胞癌的新疗法：病例报告

Int J Dermatol. 2021 Feb;60(2):233-235. doi: 10.1111/ijd.15176. Epub 2020 Sep 21.

10

Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.西米普利单抗治疗皮肤鳞状细胞癌：综述与临床病例

Oral Oncol. 2022 May;128:105847. doi: 10.1016/j.oraloncology.2022.105847. Epub 2022 Mar 31.

引用本文的文献

1

Induction chemotherapy with cemiplimab in a patient with coexistent vulvar cancer and autoimmune disease: A case report.西米普利单抗用于合并外阴癌和自身免疫性疾病患者的诱导化疗：一例报告

Gynecol Oncol Rep. 2024 Aug 14;55:101487. doi: 10.1016/j.gore.2024.101487. eCollection 2024 Oct.

2

Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab).在英国使用西普单抗的真实世界证据研究：REACT-CEMI（西普单抗治疗晚期 CSCC 的真实世界证据）。

Front Immunol. 2024 Jul 12;15:1408667. doi: 10.3389/fimmu.2024.1408667. eCollection 2024.

3